AddLife AB (ALIF-B) Fair Value & Analysis
Healthcare · SE · Market cap 20.2B SEK (≈ $2.1B) · ISIN SE0014401378
What is AddLife AB really worth?
A solid business, but trading 101% above our fair value of kr 81.17.
Strengths
Risks
For context
Fair value as of: Aug 28, 2026
From 24 valuation models · updated 8 days ago
Share price +0.2% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (kr 107.54). The favourable scenario is already priced in.
- Solid but not exceptional quality (66/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 28, 2026.
How to read this chart
60‑month range kr 54.95 – kr 379.11 · fair‑value band kr 60.87 – kr 107.54 · the kr 163.50 price screens above the kr 81.17 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 28, 2026.
Analysis
AddLife AB (ALIF-B) currently trades at kr 163.50, while our model-based Fair Value estimate is kr 81.17, implying the stock looks roughly 101.4% overvalued today. The Quality Score stands at 66/100 (solid quality), in the Healthcare sector. Bull case: the DCF Models group reads highest at a median of kr 163.26 per share, and 7 of the 24 models we run sit above the kr 163.50 price. Bear case: the Asset-Based group reads lowest at kr 31.09, and 17 of the 24 models stay below the price. Evidence for this calculation is high.
Over the trailing twelve months, AddLife AB generated revenue of 10.4B SEK at a net margin of 5.5%. Revenue declined 2.1% year over year. It earns a return on equity of 10.6%. Net debt stands at 4.0B SEK. Fundamentals as of Aug 28, 2026
Our scenario range runs from kr 60.87 (bear case) to kr 107.54 (bull case); at kr 163.50, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 21% below its 52-week high and 27% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −46% fair-value upside, at −50%, ALIF-B screens richer than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly kr 2.13 per share, which is 2.6 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 24 models by family
Widest divergence: DCF Models (kr 163.26) versus Asset-Based (kr 31.09). Highest evidence: FCF DCF (74).
Notify me when ALIF-B reaches fair value
Put ALIF-B on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 28, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 64 · Market factors (momentum, volatility) 40
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
AddLife AB (publ), together with its subsidiaries, provides instruments and equipment, consumables, and reagents primarily to medical care, research, colleges, and universities, as well as the food and pharmaceutical industries. The company operates in two segments, Labtech and Medtech.
Full company description
AddLife AB (publ), together with its subsidiaries, provides instruments and equipment, consumables, and reagents primarily to medical care, research, colleges, and universities, as well as the food and pharmaceutical industries. The company operates in two segments, Labtech and Medtech. The Labtech segment offers products, solutions, and services in the areas of diagnostics, and biomedical research and laboratory analysis. It offers products and solutions, including analytical instruments, equipment, microscopes, consumables, and reagents, as well as software support and technical services; and in the areas of microbiology, clinical chemistry, coagulation, molecular biology, research, immunology, point-of-care testing, veterinary diagnostics, as well as in the food industry. This segment also provides training programs for its customers. The Medtech segment provides medical device products for surgery, orthopaedics, critical care, endoscopy, wound care, healthcare IT, ophthalmology, home adaptation, and technical aids, as well as surgical procedures, welfare technology, and assistive devices for the elderly and disabled. It operates in Sweden, the United Kingdom, Ireland, Spain, Denmark, Norway, Italy, Finland, Switzerland, Germany, Poland, Austria, rest of Europe, and internationally. AddLife AB (publ) was founded in 1906 and is based in Stockholm, Sweden.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
AddLife AB reported revenue of 10.4B SEK in FY2025 versus 8.0B SEK in FY2021, a compound +6.9%/yr. Reported net income was 560M SEK in FY2025, compounding −6.1%/yr from FY2021.
of which total revenue +21.6 % · buybacks/dilution −3.3 %
Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).
ALIF-B screens 101% overvalued. Compare with Intuitive Surgical, Inc →
Peer Group
Medical Instruments & Supplies · 194 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Aug 28, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $367.07 | $150.04 | −59% |
| EssilorLuxottica Société anonyme EL | €160.35 | €94.93 | −41% |
| Medline Inc MDLN | $36.59 | $30.15 | −18% |
| Becton, Dickinson and Company BDX | $187.12 | $100.46 | −46% |
| Alcon Inc ALC | $72.23 | $39.78 | −45% |
| ResMed Inc RMD | A$33.19 | A$26.23 | −21% |
| West Pharmaceutical Services, Inc WST | $337.47 | $141.58 | −58% |
| Sartorius Stedim Biotech S.A DIM | €197.70 | €48.88 | −75% |
| Straumann Holding STMN | CHF 97.38 | CHF 47.31 | −51% |
| Sartorius Aktiengesellschaft SRT3 | €253.50 | €63.30 | −75% |
Compare AddLife AB with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is AddLife AB (ALIF-B) overvalued or undervalued?
What is the fair value of ALIF-B?
What is the quality score of ALIF-B?
What is the revenue of AddLife AB (ALIF-B)?
What is the net profit margin of ALIF-B?
Does AddLife AB pay a dividend?
Watch AddLife AB in the live analysis
One click puts AddLife AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.